Price movement over the last 24 hours
Abeona Therapeutics Inc vs Western Union Co — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Western Union Co trades at $7.72 (market cap $2.48B). The key difference: Western Union Co is far larger — about 6.6× Abeona Therapeutics Inc's market cap, and Western Union Co pays a 11.82% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WU | |
|---|---|---|
Market Cap | $373.32M | $2.48B |
Sector | Health | Technology |
52-Week High | $7.23 | $10.28 |
52-Week Low | $4.17 | $7.04 |
Enterprise Value | $228.22M | $2.18B |
Dividend Yield | — | 11.82% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Western Union (WU) trades at $7.95, down 0.75% on the day, with mixed technical signals but a bullish overall trend. The stock shows strong profitability with a 10.88% net margin and 47.66% ROE, and valuation metrics like a P/E of 5.87 and P/S of 0.63 appear attractive. Recent developments include a partnership with Total Wireless for fee-free money transfers and progress on the Intermex acquisition, signaling digital expansion. However, Q1 2026 earnings missed expectations, and the company faces a high debt load with a debt-to-asset ratio of 34.64% as of 2025.
The outlook for WU is cautiously optimistic, with potential upside from digital growth initiatives and a high dividend yield, but risks include competitive pressures, recent earnings volatility, and significant leverage. Analyst sentiment is mixed, with a majority Hold rating, reflecting balanced views on growth prospects versus financial constraints.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →